3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
5
Thoracic
2
Sarcoma
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Ovarian Neoplasms
24
Uterine Cervical Neoplasms
18
Fallopian Tube Neoplasms
15
Endometrial Neoplasms
13
Neoplasm Metastasis
9
Breast Neoplasms
9
Pancreatic Neoplasms
8
Uterine Cervical Dysplasia
6
Melanoma
6
Colorectal Neoplasms
6
Prostatic Neoplasms
5
Stomach Neoplasms
4
Precancerous Conditions
4
Carcinosarcoma
4
Carcinoma, Renal Cell
4
Vulvar Neoplasms
3
Uterine Neoplasms
3
Urinary Bladder Neoplasms
3
Triple Negative Breast Neoplasms
3
Squamous Intraepithelial Lesions
3
Sarcoma
3
Salivary Gland Neoplasms
3
Neoplasms
3
Carcinoma, Ovarian Epithelial
3
Carcinoma, Non-Small-Cell Lung
3
Anus Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
2
Skin Neoplasms
2
Rectal Neoplasms
2
Papillomavirus Infections
2
Interventions
pembrolizumab
24
Nivolumab
15
Magnetic Resonance Spectroscopy
7
Ipilimumab
6
avelumab
5
atezolizumab
5
Specimen Handling
5
Docetaxel
4
lenvatinib
3
durvalumab
3
Paclitaxel
3
Cyclophosphamide
3
Carboplatin
3
fludarabine
2
cabozantinib
2
aldesleukin
2
Interleukin-2
2
Fluorodeoxyglucose F18
2
FAPI-46
2
zanidatamab
1
veliparib
1
tislelizumab
1
spartalizumab
1
soluble LAG-3 protein, human
1
sargramostim
1
sacituzumab govitecan
1
rucaparib
1
regorafenib
1
poly ICLC
1
olaparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Transitional Cell
×
Biopsy
×
Gynecologic
×
Clear all
NCT05269381
2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2
Recruiting
132 enrolled